Close X
Attorney Spotlight

What colorful method does Claire Miley use to keep up with the latest healthcare regulations as they relate to proposed transactions? Find out more>

Search

Close X

Experience

Search our Experience

Experience Spotlight

On December 1, 2016, Parker Hannifin Corporation and CLARCOR Inc. announced that the companies have entered into a definitive agreement under which Parker will acquire CLARCOR for approximately $4.3 billion in cash, including the assumption of net debt. The transaction has been unanimously approved by the board of directors of each company. Upon closing of the transaction, expected to be completed by or during the first quarter of Parker’s fiscal year 2018, CLARCOR will be combined with Parker’s Filtration Group to form a leading and diverse global filtration business. Bass, Berry & Sims has served CLARCOR as primary corporate and securities counsel for 10 years and served as lead counsel on this transaction. Read more here.

CLARCOR
Close X

Thought Leadership

Enter your search terms in the relevant box(es) below to search for specific Thought Leadership.
To see a recent listing of Thought Leadership, click the blue Search button below.

Thought Leadership Spotlight

Securities Law Exchange BlogSecurities Law Exchange blog offers insight on the latest legal and regulatory developments affecting publicly traded companies. It focuses on a wide variety of topics including regulation and reporting updates, public company advisory topics, IPO readiness and exchange updates including IPO announcements, M&A trends and deal news.

Read More >

Courtney Grande Outlines DOJ $23 Million Settlement Related to Cardiac Devices

ABA Health Law Section

Publications

August 3, 2016

Bass, Berry & Sims attorney Courtney Grande authored an article for the American Bar Association's (ABA) Health Law Section outlining the February 2016 settlement between the U.S. government and 51 hospitals related to the improper implantation of cardiac devices. Under the terms of the settlement, hospitals must pay $23 million to settle the allegations they inappropriately billed Medicare for improperly implanting cardiac devices from 2002-2010. As Courtney states in the article, the "case is especially notable because it shows the dilemma faced by healthcare companies who misinterpret Centers for Medicare & Medicaid Services' (CMS) regulations and fail to recognize when CMS's assessment of appropriate care differs from the medical community's definition." This case serves to remind healthcare providers "to assess whether their practices comply with federal regulations, particularly as medical treatments continue to advance at a faster pace than CMS regulations."

The full article, "The New Cardiac Device Settlements: Why is it not Just the Number of Defendants that Makes this Case Notable," was published by the ABA's Health Law Section and is available online.


Related Professionals

Related Services

Notice

Visiting, or interacting with, this website does not constitute an attorney-client relationship. Although we are always interested in hearing from visitors to our website, we cannot accept representation on a new matter from either existing clients or new clients until we know that we do not have a conflict of interest that would prevent us from doing so. Therefore, please do not send us any information about any new matter that may involve a potential legal representation until we have confirmed that a conflict of interest does not exist and we have expressly agreed in writing to the representation. Until there is such an agreement, we will not be deemed to have given you any advice, any information you send may not be deemed privileged and confidential, and we may be able to represent adverse parties.